We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+42.02%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$301M
AUM Growth
+$81.5M
Cap. Flow
+$21.5M
Cap. Flow %
7.15%
Top 10 Hldgs %
57.04%
Holding
59
New
3
Increased
11
Reduced
10
Closed
6

Top Buys

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$11M
2
EXEL icon
Exelixis
EXEL
+$8.09M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$6.53M
4
GILD icon
Gilead Sciences
GILD
+$5.06M
5
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$4.17M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$6.4M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$3.52M
3
AMGN icon
Amgen
AMGN
+$3.19M
4
LLY icon
Eli Lilly
LLY
+$2.77M
5
INCY icon
Incyte
INCY
+$2.07M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KALV
26
DELISTED
KalVista Pharmaceuticals
KALV
$2.25M 0.75%
177,433
-50,000
-22% -$532K
TPTX
27
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$2.24M 0.74%
35,000
– –
ASND icon
28
Ascendis Pharma A/S
ASND
$16.4B
$2M 0.66%
13,800
– –
XLRN
29
DELISTED
Acceleron Pharma
XLRN
$1.73M 0.57%
18,000
– –
CRSP icon
30
CRISPR Therapeutics
CRSP
$5.74B
$1.65M 0.55%
22,000
– –
SAGE
31
DELISTED
Sage Therapeutics
SAGE
$1.57M 0.52%
37,600
– –
IMUX icon
32
Immunic
IMUX
$222M
$1.53M 0.51%
+12,300
New +$1.25M
NKTR icon
33
Nektar Therapeutics
NKTR
$2.55B
$1.5M 0.5%
4,467
– –
FOLD
34
DELISTED
Amicus Therapeutics
FOLD
$1.47M 0.49%
94,600
– –
PRNB
35
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$1.3M 0.43%
23,100
– –
QURE icon
36
uniQure
QURE
$3.44B
$1.26M 0.42%
27,500
– –
GWPH
37
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$1.24M 0.41%
10,200
– –
ALLK
38
DELISTED
Allakos
ALLK
$1.14M 0.38%
15,700
– –
AGIO icon
39
Agios Pharmaceuticals
AGIO
$2.05B
$1.14M 0.38%
21,500
– –
STRO icon
40
Sutro Biopharma
STRO
$353M
$1.1M 0.36%
13,933
– –
ARNA
41
DELISTED
Arena Pharmaceuticals Inc
ARNA
$1.04M 0.34%
16,500
– –
DCPH
42
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$994K 0.33%
17,000
– –
MNTA
43
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$970K 0.32%
27,000
– –
EXAS
44
DELISTED
Exact Sciences
EXAS
$920K 0.31%
10,700
– –
BPMC
45
DELISTED
Blueprint Medicines
BPMC
$918K 0.31%
12,000
– –
INSM icon
46
Insmed
INSM
$26.5B
$902K 0.3%
33,600
– –
KYNB
47
Kyntra Bio
KYNB
$32.4M
$799K 0.27%
788
– –
BLUE
48
DELISTED
bluebird bio
BLUE
$660K 0.22%
849
– –
GBT
49
DELISTED
Global Blood Therapeutics, Inc.
GBT
$652K 0.22%
9,800
– –
ITCI
50
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$579K 0.19%
23,000
– –
1
2
3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q2 2020 Portfolio in Review

As of Q2 2020, International Biotechnology Trust held 59 positions worth $301M, up 37% from $219M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

International Biotechnology Trust deployed $21.5M of net new capital in Q2 2020, opening 3 new positions and adding to 11 existing holdings. Its largest new stake was Regeneron Pharmaceuticals: 11,500 shares worth $7.02M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Vertex Pharmaceuticals, an estimated $3.52M trimmed.

  • International Biotechnology Trust's largest Q2 2020 buy was Regeneron Pharmaceuticals: 11,500 shares worth $7.02M.
  • International Biotechnology Trust added most to Immunomedics Inc in Q2 2020, an estimated $11M increase.
  • International Biotechnology Trust's biggest Q2 2020 reduction was Vertex Pharmaceuticals, cutting an estimated $3.52M.
  • International Biotechnology Trust fully exited Merck in Q2 2020, selling an estimated $6.4M.
  • International Biotechnology Trust's ten largest holdings make up 57% of its $301M portfolio in Q2 2020.
  • International Biotechnology Trust opened 3 new positions and closed 6 in Q2 2020.
  • International Biotechnology Trust's portfolio value rose 37% quarter-over-quarter to $301M.

Based on International Biotechnology Trust's 13F filing for Q2 2020, filed 14 Jul 2020.